[go: up one dir, main page]

AU2003284898A1 - Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer's disease - Google Patents

Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer's disease

Info

Publication number
AU2003284898A1
AU2003284898A1 AU2003284898A AU2003284898A AU2003284898A1 AU 2003284898 A1 AU2003284898 A1 AU 2003284898A1 AU 2003284898 A AU2003284898 A AU 2003284898A AU 2003284898 A AU2003284898 A AU 2003284898A AU 2003284898 A1 AU2003284898 A1 AU 2003284898A1
Authority
AU
Australia
Prior art keywords
combinative
nicotinic
alzheimer
disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003284898A
Other languages
English (en)
Inventor
Stacy A. Castner
Graham V. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Micro Inc
Original Assignee
MIICRO Inc
Micro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MIICRO Inc, Micro Inc filed Critical MIICRO Inc
Publication of AU2003284898A1 publication Critical patent/AU2003284898A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003284898A 2002-10-29 2003-10-24 Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer's disease Abandoned AU2003284898A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42204702P 2002-10-29 2002-10-29
US60/422,047 2002-10-29
PCT/US2003/033729 WO2004039321A2 (fr) 2002-10-29 2003-10-24 Therapie associee agoniste nicotinique/agoniste d1 pour le traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
AU2003284898A1 true AU2003284898A1 (en) 2004-05-25

Family

ID=32230314

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003284898A Abandoned AU2003284898A1 (en) 2002-10-29 2003-10-24 Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer's disease

Country Status (2)

Country Link
AU (1) AU2003284898A1 (fr)
WO (1) WO2004039321A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
CA2799744C (fr) 2010-05-17 2020-01-28 Envivo Pharmaceuticals, Inc. Forme cristalline de monohydrate d'hydrochlorure de (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide
US9585877B2 (en) 2012-05-08 2017-03-07 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function

Also Published As

Publication number Publication date
WO2004039321A8 (fr) 2005-05-26
WO2004039321A2 (fr) 2004-05-13

Similar Documents

Publication Publication Date Title
AU2003206413A1 (en) Substituted amino carboxamides for the treatment of alzheimer's disease
AU2003229937A1 (en) Alkynyl-substituted spirocyclic sulfamides for the treatment of alzheimer's disease
EP1392287B8 (fr) Usage de dérivés de l'azétidinone pour le traitement de la maladie d' Alzheimer.
HUS1500043I1 (hu) Eljárások Parkinson-kór kezelésére
SI1303272T1 (sl) Derivati benzotiazola za zdravljenje alzheimerjeve bolezni in parkinsonove bolezni
AU2003286567A1 (en) Methods for the treatment of skin disorders
AU2002306848A1 (en) Methods of treating alzheimer's disease with piperidin derivates
AU2003217275A1 (en) Azabicyclic compounds for the treatment of disease
AU2002315131A1 (en) Aminediols as agents for the treatment of alzheimer's disease
AU2002335794A1 (en) Allylamides useful in the treatment of alzheimer's disease
AU2002312897A1 (en) Drugs for the treatment of the alzheimer disease
AU2003254146A1 (en) Methods for the treatment of parkinson's disease
AU2003303141A1 (en) Hydroxypropyl amides for the treatment of alzheimer's disease
AU2003284898A1 (en) Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer's disease
AU2003238046A1 (en) Substituted 3- and 4- aminomethylpiperidines for use as beta-secretase in the treatment of alzheimer's disease
AU2003273310A1 (en) Substituted aminoethers for the treatment of alzheimer's disease
EP1181550A4 (fr) Procedes d'identification de composes pour le traitement de la maladie d'alzheimer
AU2003299101A1 (en) Compounds for the treatment of alzheimer's disease
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
GB0201025D0 (en) The treatment of degenerative diseases
AU2003286530A1 (en) Substituted peptides useful in the treatment of alzheimer's disease
AU2003295504A8 (en) Development of therapeutics for the treatment of endotoxin-mediated diseases
AU2003216696A1 (en) Methods for the selection of compounds useful for the treatment of huntington's disease
AU2003260745A1 (en) Sulphonylamino derivatives for the treatment of alzheimer's disease
AU2002365654A1 (en) Treatment of diseases via the skin

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase